Atherosclerosis: the importance of HDL cholesterol and prostacyclin: a role for niacin therapy.
Niacin reduces the incidence of non-fatal myocardial way infarction, confers a significant long-term survival benefit after recovery from myocardial infarction, and has had many years of study and usage by the medical community. Recent evidence suggests that via mechanisms which elevate HDL cholesterol and also release endogenous prostacyclin, niacin should be a potent agent in the long-term treatment of atherosclerosis.
Luria
M H
MH
Department of Cardiology, Hadassah University Hospital, Jerusalem, Israel.
D000818:Animals; D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy / Q000378:metabolism*; D008076:Cholesterol, HDL / Q000097:blood / Q000378:metabolism*; D011464:Epoprostenol / Q000097:blood / Q000378:metabolism*; D006801:Humans; D009525:Niacin / Q000627:therapeutic use
D008076:Cholesterol, HDL; D009525:Niacin; D011464:Epoprostenol